Erythropoietin for cancer-associated malignant anemia: A meta-analysis

FENG ZHAO¹*, YIJUAN WANG¹*, LIN LIU² and MEILING BIAN³

¹Department of Blood Transfusion Medicine, Linzi District People’s Hospital, Binzhou Medical University; ²Medical Intensive Care Unit, PKU Care Luzhong Hospital; ³Department of Internal Medicine, Linzi District People’s Hospital, Binzhou Medical University, Zibo, Shandong 255400, P.R. China

Received October 17, 2016; Accepted March 23, 2017

DOI: 10.3892/mco.2017.1254

Abstract. The present study aimed to evaluate the effectiveness of erythropoietin (EPO) for improving cancer-associated malignant anemia. A search was performed for randomized clinical trials, conducted according to the Cochrane manual, using electronic databases including PubMed, EMBASE, the Cochrane Library and ClinicalTrials.gov up to 15 August 2015. A total of 6 eligible studies from 5 articles enrolling a total of 453 patients were entered into the current meta-analysis. Upon EPO treatment, there were significant differences in the change in hemoglobin (HB) levels compared with the placebo at short-term follow-up [mean difference (MD)=0.66; 95% confidence interval (CI), 0.14-1.18; I²=Not applicable; P=0.01] and long-term follow-up (MD=0.10; 95% CI, 0.02-0.18; I²=Not applicable; P=0.01) under the random effects model. For changes in hematocrit (HCT) compared with the placebo, the results revealed there were significant differences at short-term follow-up (MD=2.47; 95% CI, 0.75-4.19; I²=Not applicable; P=0.005) and long-term follow-up (MD=7.60; 95% CI, 6.15-9.05; I²=Not applicable; P<0.00001) under the random effects model. Compared with the placebo in short-term follow-up under the fixed effects model with homogeneity, the result was a significant difference for the transfusion ratio [relative risk (RR)=0.81; 95% CI, 0.67-0.97; I²=34%; P=0.02] and the transfusion requirements (MD=−0.45; 95% CI, −0.92, 0.03; I²=6%; P=0.07). Funnel plots did not detect any publication bias. These results suggest that EPO was beneficial to alleviate cancer-associated anemia and improve survival outcomes for patients with cancer.

Introduction

Cancer anemia, also known as cancer-associated malignant anemia, is a common clinical symptom of cancer, with a rate of incidence approaching 50% of cancer cases (1,2). There are several causes of cancer-associated malignant anemia, such as bleeding, hemolysis, lack of nutrition, bone marrow necrosis and fibrosis caused by tumor cell infiltration, direct inhibition of red blood cells caused by radiotherapy and chemotherapy, relative insufficiency of erythropoietin (EPO) secretion (3), hematopoietic inhibition and influence of iron metabolism and reduced reactivity of EPO and cytokines from cancerous human bone marrow (4-6). Malignant tumor anemia is a common complication in various malignant tumors, in which red blood cell depletion leads to inadequate tissue oxygenation, reducing the sensitivity of tumors to radiation and chemotherapy, thereby lowering the patient’s quality of life, decreasing survival time and affecting overall prognosis (4,7,8). At 3 years post-cancer diagnosis, mortality among patients with anemia is twice as high as that among those without anemia (9-12). Clinically speaking, quality of life and adverse events are important predictors in patients with cancer (8).

At present, there are four methods for treating cancer-associated anemia: Blood transfusion (primarily red blood cell suspension), iron supplements (reduced iron deposits caused by EPO treatment), change of treatment scheme and administration of stimulating factor (4,13). Blood transfusion is not without risks, particularly for patients with cancer. Blood transfusions may decrease the survival rate, and tumor recurrence may occur following blood transfusion, which may lead to poor prognosis. The effect of iron supplements alone is often slow, with low efficacy (2.5). EPO is a type of high-purity active glycoprotein produced using genetically modified technology, and it specifically stimulates bone marrow hematopoietic cells (13-15). Although a large body of research has demonstrated that the EPO is able to improve the symptoms of cancer-associated malignant anemia, this conclusion remains...
controversial. In order to assess the efficacy of EPO in this setting, the current study conducted a meta-analysis of the available research.

Materials and methods

Search strategy. A series of electronic searches of PubMed, EMBASE, the Cochrane Library and ClinicalTrials.gov up to 8 February 2016 for eligible randomized or parallel-group design clinical trials investigating EPO for the treatment of cancer-associated malignant anemia was performed using the following Medical Subject Headings and text words: ‘neoplasm*’, ‘tumor*’, ‘cancer*’, ‘erythropoietin’ and ‘anaemia*’.

Inclusion criteria. All studies were selected in accordance with following inclusion criteria: (1) All studies were randomized or parallel-group design clinical trials; (2) eligible studies included patients with cancer-associated malignant anemia patients older than 18 years; (3) the entire study population was patients diagnosed with cancer with malignant solid tumors confirmed by histology or cytology; (4) the hemoglobin (HB) levels of the patients were >8.5 and <13.5 g/dl; (5) eligible studies included at least one of the following outcomes: Change in HB, change in hematocrit (HCT), the ratio of transfusion and transfusion requirements during the treatment.

Exclusion criteria. Studies were excluded in accordance with following criteria: (1) The study reported that the patients had received radiation, chemotherapy, or surgery prior to or during receiving EPO; (2) anemia was not caused by cancer; (3) the study included primary hematologic disease, seizure disorder, uncontrolled hypertension, recent history of thromboembolic disease (within 1 year), other clinically significant systemic disease, an active infectious process, pregnancy, ongoing blood loss, scheduled autologous blood donation or blood transfusion within the previous 30 days; (4) duplicate published research was excluded; (5) the data could not be extracted or obtained through contact with the original author.

Data extraction. The relevant information including study design, patients' characteristics, the criteria of tumor staging, tumor staging, the initial HB levels, interventions, controls and outcomes (change in HB, change in HCT, the ratio of transfusion or transfusion requirements) were independently extracted and entered it into a database by two investigators. When relevant research information was missing, particularly design or outcomes, the original authors were contacted for clarifications. Then, intention-to-treat (ITT) datasets were used for all outcomes whenever available. Disagreements between the two authors on data extraction were resolved by discussion. If the dispute persisted, other senior investigators were consulted to reach a consensus.

Statistical analysis. For the outcomes based on dichotomous data (16,17), relative risk (RR) as was utilized as an effect estimator, while for continuous outcomes mean difference (MD) was used (17,18). Subsequently, 95% confidence intervals (CIs) and P-values were calculated using RevMan 5.3 software (Cochrane Collaboration, London, UK) in all outcomes. A statistical test for heterogeneity was performed and an I²>40 was adopted as evidence for heterogeneity according to the Cochrane handbook (19). If the data were heterogeneous under the fixed effects model, a random effects model was utilized (20). Through observing asymmetry of funnel plots, publication bias was evaluated qualitatively (21). In a funnel plot, larger studies that provide a more precise estimate of an intervention's effect form the spout of the funnel, whereas smaller studies with less precision form the cone end of the funnel. Asymmetry in the funnel plot indicates potential publication bias. P≤0.05 was considered to indicate a statistically significant difference.

Results

Study selection and data collection. In total, 453 publications were obtained from electronic databases (Fig. 1). Based on the selection criteria, quantitative data was obtained for the current meta-analysis by reading all titles, abstracts and performing full text evaluations. Finally, 6 eligible studies from 5 articles were entered into the meta-analysis.

Study characteristics. The search obtained 6 eligible studies from 5 articles (22-26), which enrolled a total of 595 patients. The change in HB was reported in 2 studies (23,26), the transfusion requirements were noted from 3 studies (23,25), the ratio of transfusion was obtained from a total of 233 of 495 patients from 5 studies (22-26) and the change in HCT was reported in 2 studies (23,26). Table I presents the clinical characteristics from all studies.

Change in HB. The change in HB levels is presented in Fig. 2; each included study suggested statistically significant improvements upon treatment with EPO. Compared with placebo, the results revealed there were significant differences
<table>
<thead>
<tr>
<th>First author</th>
<th>Year</th>
<th>Country</th>
<th>Sample (F, I/C)</th>
<th>Age (I/C)</th>
<th>Criteria of tumor staging</th>
<th>Tumor Tumor HB  Usage, Dosage, Frequency</th>
<th>EPO type</th>
<th>Usage, Dosage, Frequency</th>
<th>Intervention</th>
<th>Control</th>
<th>ITT/PP (Refs.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kettelhack</td>
<td>1998</td>
<td>Germany</td>
<td>48 (27)/ 54 (32)</td>
<td>71 (53-87)/ 67 (37-91)</td>
<td>NA</td>
<td>NA</td>
<td>CC</td>
<td>11.5 (10.5-12.5)/ 12.0 (11.0-13.1)</td>
<td>EPO</td>
<td>EPO 20,000 IU/day</td>
<td>Placebo</td>
</tr>
<tr>
<td>Scott</td>
<td>2002</td>
<td>USA</td>
<td>29 (13)/ 29 (11)</td>
<td>67.6±11.0/ 61.8±10.8</td>
<td>AJCC 1997</td>
<td>I, II, III, IV</td>
<td>PC, BM</td>
<td>10-13.5</td>
<td>EPO 150 IU/kg/day, 200 mg/day FeSO₄, BID by FeSO₄</td>
<td>Placebo, 100 mg/day iron</td>
<td>PP (23)</td>
</tr>
<tr>
<td>Kosmadakis</td>
<td>2003</td>
<td>Greece</td>
<td>31 (16)/ 32 (13)</td>
<td>67.1±2.1/ 66.4±2</td>
<td>NA</td>
<td>NA</td>
<td>Stomach 18%/19%, Colon 53%/52%, Rectum 29%/29%</td>
<td>EPO</td>
<td>EPO 100 mg/day</td>
<td>Placebo, 100 mg/day iron</td>
<td>ITT (24)</td>
</tr>
<tr>
<td>Christodoulakis</td>
<td>2005</td>
<td>Greece</td>
<td>67 (37)/ 68 (40)</td>
<td>71 (36-92)/ 70 (44-89)</td>
<td>A and B</td>
<td>Dukes A and B 28/26, C and D 31/32, unknown 8/10</td>
<td>CC</td>
<td>9-12</td>
<td>EPO 300 IU/kg/day, 200 mg/day iron</td>
<td>200 mg/day ITT (25)</td>
<td></td>
</tr>
<tr>
<td>Christodoulakis</td>
<td>2005</td>
<td>Greece</td>
<td>69 (38)/ 68 (40)</td>
<td>72.5 (43-91)/ 70 (44-89)</td>
<td>A and B</td>
<td>Dukes A and B 35/26, C and D 29/32, unknown 5/10</td>
<td>CC</td>
<td>9-12</td>
<td>EPO 150 IU/kg/day, 200 mg/day iron</td>
<td>200 mg/day ITT (25)</td>
<td></td>
</tr>
<tr>
<td>Mystakidou</td>
<td>2005</td>
<td>Greece</td>
<td>50 (28)/ 50 (33)</td>
<td>63 (32-79)/ 64.5 (41-79)</td>
<td>NA</td>
<td>NA</td>
<td>PC 36%/16%, CC 16%/16%, GS 32%/22%, C: LC 18%</td>
<td>EPO</td>
<td>EPO 40000 IU QD/BID, 200 mg/day iron</td>
<td>200 mg/day ITT (26)</td>
<td></td>
</tr>
</tbody>
</table>

AJCC, the American Joint Committee on Cancer; BM, Bone metastases; HB, Hemoglobin; I, Intervening group; C, Control group; CC, Colonic carcinoma; EPO, erythropoietin; F, female; GS, Genital system; ITT, Intention-to-treat; LC, lung cancer; PC, Prostate cancer; PP, Per protocol; NA, Not applicable; TNM, Tumor Node Metastasis; IU, international units; QD, daily; BID, twice daily.
in the short-term follow-up [MD=-0.66; 95% CI, 0.14-1.18; \(I^2\)=Not applicable (NA); \(P=0.01\)] and the long-term follow-up (MD=0.10; 95% CI, 0.02-0.18; \(I^2\)=NA; \(P=0.01\)). However, the overall result revealed that there was not a significant difference (MD=0.32; 95% CI, -0.02-0.85; \(I^2\)=77%; \(P=0.24\)) under substantial heterogeneity.

**Ratio of transfusion.** As presented in Fig. 4, for the ratio of transfusion only one study (24) suggested statistically significant improvements, upon EPO treatment. Compared with placebo, the overall meta-analysis result revealed that there was no significant difference (MD=-0.45; 95% CI, -0.92-0.03; \(I^2\)=6%; \(P=0.07\)) at short-term follow-up under weak homogeneity.

**Publication bias.** There was no potential publication bias based on symmetry from a funnel plot of the ratio of transfusion outcome (Fig. 6).

**Discussion**

There are several potential causes of cancer-associated malignant anemia. These include bleeding, hemolysis, poor nutrition, radiotherapy and chemotherapy. However, as anemia reflects a shortage of red blood cells, which are produced in the bone marrow, cancer-associated anemia can also be caused by the inability of the bone marrow to produce them due to a relative deficiency of EPO. To establish if EPO significantly increased HB levels, and whether this was associated with improved energy levels and a reduction in blood transfusions, the current meta-analysis was performed with 6 eligible studies from 5 articles that included patients with cancer-associated anemia. The efficacy of EPO for cancer-associated malignant anemia was evaluated by measuring four types of outcome.

The results revealed that EPO improved HB levels, based on the change in HB, independent of the follow-up duration. While the overall result was not statistically significant, the finding is
supported by previous studies (26, 27). The overall result did not reach statistical significance primarily due to the small sample size. Cancer-associated anemia reduced the HCT level below normal, which was reversed by EPO at the short-and long-term follow-ups. With respect to transfusion requirements and the ratio of transfusion, EPO reduced the need for transfusions. The HB levels were increased owing to stimulation by EPO, which improved the patients' anemic state, thereby reducing the demand for transfusions. EPO is a highly glycosylated (40% of total molecular weight) compound with half-life of ~5 h in the blood, which may vary between its endogenous and various recombinant versions (28). Additional glycosylation or other alterations of EPO via recombinant technology increases its stability in blood (thus reducing the frequency of injections required) (29). EPO binds to the EPO receptor on the red cell progenitor surface and activates a Janus kinase 2 signaling cascade. EPO receptor expression is found in a number of tissues, such as bone marrow and peripheral/central nervous tissue. In the bloodstream, red cells themselves do not express EPO receptors, so they are not able to respond to EPO (30). However, indirect dependence of red cell longevity in the blood on plasma erythropoietin levels has been reported, a process termed neocytolysis (31). The majority of anemic patients with cancer of the gastrointestinal tract have iron deficiency due to subclinical blood loss; therefore, an iron supplement has been advocated (32). In particular, anemia is common in patients with colorectal cancer, as they are more likely to experience a loss and malabsorption of iron (33). However, iron supplementation (5, 34) has not been found to be able to stimulate erythropoiesis to a sufficient degree to facilitate autologous blood donation or to reduce the need for allogeneic blood transfusions in patients with cancer (32). This may be due to a reticulo-endothelial blockage of iron, characteristic of several other conditions observed in these patients (35). The treatment scheme combining EPO with iron resulted in a more profound HB increase with intravenous iron, which may contribute to a superior optimization of the patient's condition and possibly a decrease in postoperative morbidity (33).

The advantage of the current meta-analysis was that it included studies to explain the effect of EPO from four comprehensive aspects of blood indicators (20). The study had several limitations. Firstly, only a small number of trials met the inclusion/exclusion criteria, and the meta-analysis may have benefitted from more associated clinical research to support its findings (17). Secondly, certain trials had missing data (36), which was a source of heterogeneity, and the current study was unable to perform meta-regression for confounding factors.

In conclusion, the current study suggests that EPO reduces cancer-associated anemia as well as improving relevant blood parameters among this patient population.

References


